Clinical Trial Update: Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus [Phase 3]

View source ↗

Summary

Phase 3 safety and efficacy study of daclatasvir with pegylated interferon alfa-2a and ribavirin in patients with untreated hepatitis C genotype 1 coinfected wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Hepatitis C

Drugs mentioned

• Daclatasvir (daclatasvir)
• Pegylated interferon alfa-2a (Peginterferon alfa-2a)
• Ribavirin (ribavirin)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatitis C, Genotype 1 | Phase 3 | Status: COMPLETED | Results posted: 2015-12-17